GKOS NYSE
Glaukos Corporation
1W: +6.9%
1M: +15.5%
3M: +17.9%
YTD: +61.1%
1Y: +137.1%
3Y: +167.9%
5Y: +293.3%
$181.22
+2.95 (+1.65%)
After Hours: $181.47 (+0.25, +0.14%)
Weekly Expected Move ±5.9%
$158
$168
$179
$189
$200
Credit Risk of going bust: lower than 83% of companies Debt: 1.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.19 (down 99.9%), Glaukos Corporation would be worth roughly what it owes.
Total debt $102.8M against a stock market value of $10.52B.
Distance to default 10.47 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $51.4M (short-term plus half of long-term), stock volatility 50.3%; Altman Z 25.58. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.19 (down 99.9%), Glaukos Corporation would be worth roughly what it owes.
Total debt $102.8M against a stock market value of $10.52B.
Distance to default 10.47 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $51.4M (short-term plus half of long-term), stock volatility 50.3%; Altman Z 25.58. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
2 neutral
0 bearish
Articles (24h)
2
Hourly Sentiment (24h)
0.45
Bullish
5 bullish
2 neutral
1 bearish
Articles (7d)
8
Daily Sentiment (7 Days)
Articles (100)
WST Q3 Earnings Preview: Will HVP Strength Offset Vantage Weakness?
GEHC Ahead of Q3 Earnings: Can Strong Demand Offset Macro Headwinds?
INSP Stock Gains 47.8% in Three Months: What's Driving the Rally?
DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?
BDX Stock Gains 25.5% in Six Months: What's Behind the Rally?
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Intuitive Surgical's Q3 Earnings Beat Estimates on Strong System Sales
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
State of Alaska Department of Revenue Sells 9,393 Shares of Glaukos Corporation $GKOS
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
Glaukos' iDose TR meets primary goal in phase 4 trial
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
Glaukos slips as insider selling overshadows positive trial data for eye therapy
Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Bank of America Corp DE Purchases Shares of 587,327 Glaukos Corporation $GKOS
10 large and mega-cap U.S. healthcare stocks with the strongest momentum grades
Glaukos Corporation $GKOS Shares Sold by Squarepoint Ops LLC
Idexx (IDXX) Down 7.8% Since Last Earnings Report: Can It Rebound?
Small-cap bears were back. Was IWM the warning sign?
Ten healthcare stocks leading in year-over-year CapEx growth
Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?
Corient Private Wealth LP Takes Position in Glaukos Corporation $GKOS
Canada Pension Plan Investment Board Acquires New Position in Glaukos Corporation $GKOS
Glaukos (GKOS) Up 8% Since Last Earnings Report: Can It Continue?
Glaukos Corporation $GKOS Stock Holdings Trimmed by Algert Global LLC
61,957 Shares in Glaukos Corporation $GKOS Purchased by Deutsche Bank AG
GKOS Stock Surges 67% Year to Date: What's Driving the Rally?
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Corcept, Revolution Medicines lead ten large-cap healthcare stocks surging in 2026
Glaukos (GKOS) Q2 2026 Earnings Call Transcript
Can da Vinci 5 Drive Intuitive Surgical's Next Multi-Year Upgrade Cycle?
First Trust Advisors LP Acquires 40,798 Shares of Glaukos Corporation $GKOS
Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up
Glaukos (NYSE:GKOS) Reaches New 1-Year High on Strong Earnings
Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
Bank of New York Mellon Corp Sells 12,667 Shares of Glaukos Corporation $GKOS
Glaukos Corporation (NYSE:GKOS) Given Average Rating of “Moderate Buy” by Analysts
Can ISRG Maintain Its Premium Valuation Amid Slower Procedure Growth?
Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?
GKOS Stock Up More Than 45% Since May-End: What's Driving the Rally?
Can ISRG's 'Quintuple Aim' Strategy Continue to Justify Premium Pricing?
Delta Air Lines To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
Glaukos Corporation (GKOS) Stock Analysis: Exploring a 28.5% Potential Upside with a Strong Buy Consensus - DirectorsTalk Interviews
The Technical Signals Behind (GKOS) That Institutions Follow - Stock Traders Daily
Glaukos (GKOS) Valuation Check After Recent Share Price Pullback And Growth Narrative - simplywall.st
Glaukos Stock Falls 14% In A Single Day, Now Is Not The Time To Buy The Stock - Trefis
The Bear Case: How GKOS Behaves During Market Shocks - Trefis
Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure - Quiver Quantitative
Glaukos Plunges 11.2% After BTIG Maintains Buy - AlphaStreet
GKOS Maintained by BTIG -- Price Target Raised to $162 - GuruFocus
Nvidia To Rally More Than 123%? Here Are 10 Top Analyst Forecasts For Thursday
New Analyst Forecast: $GKOS Given $162 Price Target - Quiver Quantitative
Glaukos Insider Makes Major Move With High-Value Stock Sale - TipRanks
Glaukos director Kliman sells $703,800 in stock By Investing.com - Investing.com Nigeria
Director at Glaukos (NYSE: GKOS) exercises options and sells 5,000 shares - Stock Titan
Glaukos stock hits 52-week high at $146.90 By Investing.com - Investing.com Nigeria
Glaukos Corporation (GKOS) Stock Analysis: Strong Buy Ratings Signal Promising Upside in the Medical Device Arena - DirectorsTalk Interviews
Janus Henderson Group (GKOS) discloses 5.35M shares, 9.2% holding - Stock Titan
Gilbert H. Kliman (GKOS) files Form 144 to sell 5,000 shares - Stock Titan
Insider Sale: Director at $GKOS Sells 5,000 Shares - Quiver Quantitative
Director at Glaukos (NYSE: GKOS) exercises options and sells 5,000 shares - Stock Titan
Glaukos Announces Participation in Upcoming Investor Conferences
Glaukos Announces Participation in Upcoming Investor Conferences - Business Wire
How to watch Glaukos at four upcoming investor conferences - Stock Titan
Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight
Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight
Alex Thurman Sells 10,000 Shares of Glaukos (NYSE:GKOS) Stock - MarketBeat
How The Glaukos (GKOS) Narrative Is Shifting With New Guidance And Product Ramp Expectations
Glaukos Stock Leaps 23% In One Day, Now Is Not The Time To Buy The Stock - Trefis
Two Medical Stocks Skyrocket After Demolishing Views — And One Is About To Break Out
12 Health Care Stocks Moving In Thursday's Intraday Session
Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook
Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Glaukos Q1 Earnings Call Highlights
Glaukos Corp (GKOS) Q1 2026 Earnings Call Highlights: Record Sales Surge and Raised Guidance
Glaukos outlines $620M-$635M 2026 net sales outlook following Q1 outperformance
Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Glaukos Corporation Q1 2026 Earnings Call Summary
Glaukos Corporation Q1 2026 Earnings Call Summary
Glaukos (GKOS) Q1 2026 Earnings Transcript
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
12 Health Care Stocks Moving In Wednesday's After-Market Session
Glaukos Non-GAAP EPS of -$0.18 beats by $0.10, revenue of $150.6M beats by $13.6M
Glaukos Announces First Quarter 2026 Financial Results
Here are the major earnings after the close Wednesday
Is ISRG's International Weakness a Temporary Drag or Structural Risk?
Is ISRG's International Weakness a Temporary Drag or Structural Risk?
Earnings Scheduled For April 29, 2026
Eye-device maker Glaukos lifts outlook after $150.6M quarter - Stock Titan
April 2026's Top 3 Stocks That May Be Trading Below Estimated Fair Value
3 Stocks That Might Be Undervalued By Up To 32.8%
3 Stocks That Might Be Undervalued By Up To 48.3% Offering A Possible Discount